A Chinese girl with Leigh syndrome: Effect of botulinum toxin on dystonia

Journal of Paediatrics and Child Health

Volumn 34, Issue 5, 1998, Pages 480-482

  Leung, T F ^a,b   Hui, J ^a   Yeung, W L ^a   Goh, K ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Bladder dystonia; Botulinum toxin; Leigh syndrome; Muscle dystonia; Respiratory chain complex I deficiency

Indexed keywords

BACLOFEN; BOTULINUM TOXIN; BOTULINUM TOXIN A; CARBIDOPA PLUS LEVODOPA; CYTOCHROME C OXIDASE; LACTIC ACID; MITOCHONDRIAL DNA; MUSCLE RELAXANT AGENT; PYRUVATE DECARBOXYLASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); THIAMINE; TRIHEXYPHENIDYL;

ARTICLE; BLADDER MUSCLE; BRAIN INFARCTION; CASE REPORT; CHINESE; DRUG EFFECT; DYSTONIA; ENZYME DEFICIENCY; FEMALE; HUMAN; HUMAN CELL; HYPERLACTATEMIA; INTRAMUSCULAR DRUG ADMINISTRATION; LEIGH DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; SKIN FIBROBLAST;

BIOPSY; BOTULINUM TOXIN TYPE A; CHILD, PRESCHOOL; DYSTONIA; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; LEIGH DISEASE; MAGNETIC RESONANCE IMAGING; NEUROMUSCULAR AGENTS; URINARY BLADDER, NEUROGENIC;

EID: 0031726136     PISSN: 10344810     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1754.1998.00275.x     Document Type: Article

References (16)

1. Shoffner JM, Wallace DC. Oxidative phosphorylation diseases. In Scriver CR, Beaudet AL, Sly WL, Valle D, eds. The Metabolic Basis of Inherited Disease, vol 1, 7th edn. McGraw Hill, New York, 1995; 1535-609.
2. Miyabayashi S, Ito T, Narisawa K. Biochemical study in 28 children with lactic acidosis, in relation to Leigh's encephalomyelopathy. Eur. J. Pediatr. 1985; 143: 278.
3. Morris AA, Leonard JV, Brown GK et al. Deficiency of respiratory chain complex I is a common cause of Leigh disease. Ann. Neurol. 1996; 40: 25-30.
4. Rahman S, Blok RB, Dahl HH et al. Leigh syndrome: clinical features and biochemical and DNA abnormalities. Ann. Neurol. 1996; 39: 343-51.
5. Robinson BH, De Meirleir L, Glerum M, Sherwood G, Becker L. Clinical presentation of mitochondrial respiratory chain defects in NADH-coenzyme Q reductase and cytochrome oxidase: clues to pathogenesis of Leigh disease. J. Pediatr. 1987; 110: 216-22.
6. De Vivo DC, DiMauro S. Mitochondrial diseases. In Swaiman KF, ed. Pediatric Neurology - Principles and Practice, vol 2, 2nd edn. Mosby, St. Louis, 1994; 1335-53.
7. Ton C, Hwang DM, Dempsey AA, Liew CC. Identification and primary structure of five human NADH-ubiquinone oxidoreductase subunits. Biochem. Biophys. Res. Common. 1997; 214: 589-94.
8. Pitkanen S, Feigenbaum A, Laframboise R, Robinson BH. NADH-coenzyme Q reductase (complex I) deficiency: heterogeneity in phenotype and biochemical findings. J. Inherit. Metab. Dis. 1996; 19: 675-86.
9. Robinson BH. Lacticacidemia. Biochim. Biophys. Acta 1993; 1182: 231-44.
10. Botox. In Gillis MC, Welbanks L, Bergeron D, eds. Compendium of Pharmaceuticals and Specialties, 32nd edn. Canadian Pharmaceutical Association, Ottawa, 1997; 194-7.
11. Pierson SH, Katz DI, Tarsy D. Botulinum toxin A in the treatment of spasticity: Functional implications and patient selection. Arch. Phys. Med. Rehabil. 1996; 77: 717-21.
12. Snow BJ, Tsui JKC, Bhatt MH, Varelas M, Hashimoto SA, Calne DB. Treatment of spasticity with botulinum toxin: A double blind study. Ann. Neurol. 1990; 28: 512-5.
13. Yoshimura DM, Aminoff MJ, Olney RK. Botulinum toxin therapy for limb dystonias. Neurology 1992; 42: 627-30.
14. Cosgrove AP, Corry IS, Graham HK. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev. Med. Child Neurol. 1994; 36: 386-96.
15. Gooch JL, Sandell TV. Botulinum toxin for spasticity and athetosis in children with cerebral palsy. Arch. Phys. Med. Rehabil. 1996; 77: 508-11.
16. Koman CA, Modney JF, Smith B, Goodman A, Mulvaney T. Management of cerebral palsy with botulinum-A toxin: preliminary investigation. J. Pediatr. Orthop. 1993; 13: 489-95.